Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Wilms Tumor 1Sarcoma 1Peripheral Nervous System Diseases 1Neurotoxicity Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1Leukemia 1Kidney Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1

Interventions

Carboplatin 330Pemetrexed 266Cisplatin 234Docetaxel 195Paclitaxel 182Radiotherapy 181Erlotinib Hydrochloride 153pembrolizumab 147Gemcitabine 147Bevacizumab 125Drug Therapy 121Radiosurgery 115Nivolumab 112osimertinib 92durvalumab 88Gefitinib 67atezolizumab 63Vinorelbine 63Surgical Procedures, Operative 62Magnetic Resonance Spectroscopy 54anlotinib 42Immunotherapy 42Taxes 39Blood Specimen Collection 39Ipilimumab 38130-nm albumin-bound paclitaxel 38Specimen Handling 36Immune Checkpoint Inhibitors 35Radiation 34Albumin-Bound Paclitaxel 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Non-Small-Cell Lung × Glutamic Acid × Clear all
NCT04585490 2026-05-04

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Stanford University

Phase 3 Recruiting
48 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡